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internally and externally validated, the deterministic and probabilistic sensitivity 
analyses were performed to evaluate uncertainty. A base-case analysis was per-
formed for the population of real surgical candidates in both countries. Cost data 
are presented in 2012 euros. Results: In Germany, in the base-case analysis over 
10 years bariatric surgery led to incremental cost of € 2,909 and generated additional 
0.03 years of life and 1.2 quality-adjusted life years (QALYs) with incremental cost-
effectiveness ratio of € 2,457/QALY. Over lifetime, surgery led to savings of € 8,522, 
and generated additional 0.7 years of life, and 3.2 QALYs. In France, in the base-case 
analysis over 10 years bariatric surgery led to incremental cost of € 1,106 and gener-
ated additional 1.3 QALYs with incremental cost-effectiveness ratio of € 852/QALY. 
Over lifetime surgery lead to savings of € 8,359, additional 0.5 life years, and 3.4 
QALYs. In both countries surgery was also associated with reduction of incidence 
of diabetes and cardiovascular disorders. One- to three-year delay in provision of 
surgery led to reduction of clinical effectiveness, but had diverse impact on total cost 
in different patient cohorts. ConClusions: In a comprehensive decision analytic 
model, a current mix of surgical methods for bariatric surgery was cost-effective 
at 10 years and cost saving over the lifetime time horizon in Germany and France.
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objeCtives: Obesity is on the rise globally, especially in developed countries and 
Australia is no exception. Currently, the most effective treatment for sustainable 
weight loss is bariatric surgery. This study is the first of its kind to assess the 
cost-effectiveness of 3 bariatric surgery procedures in comparison with standard 
care in Australia. Methods: A decision analytic model incorporating Markov 
process will be undertaken to compare adjustable gastric banding (AGB), Roux-
en-Y Bypass (RYGB) and sleeve gastrectomy (SG) against standard care. The states 
will be based on BMI categories obtained from WHO and NICE guidelines. The 
cycle length will be one year and, owing to the limited availability of long-term 
data for bariatric procedures, the model will have a time horizon of 10 years. 
Utilities will be based on the SF-6D and transition probabilities will be derived 
from a network meta-analysis of BMI reductions as the treatment effect for the 
various comparators. Cost data will be obtained from the Australian Institute 
of Health and Welfare (AIHW). Construction of the model will be carried out via 
Microsoft Excel and the results will be presented as a comparison of costs and 
quality-adjusted-life years (QALYs) to generate ICERs for each of the interven-
tions. One-way sensitivity analysis in addition to PSA will be carried out to test 
the robustness of the model in terms of the assumptions made and various input 
parameters. Results: Construction of the model has already commenced and 
will be finished by mid-July; full completion of the write-up will be completed by 
the end of July. This research is carried out in conjunction between City University 
London and Griffiths University (Brisbane, Australia). ConClusions: To be com-
pleted by 15/07/2015.
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objeCtives: Haemophilia A causes a considerable burden on society. While prophy-
laxis in children aged ≤ 2y is now a gold standard treatment, the benefits of late 
secondary prophylaxis are still controversial. Aim of this study is to estimate the 
cost-utility of antihemophilic factor rFVIII-FS (Kogenate® FS) in secondary prophy-
laxis vs on-demand regimen from the Italian healthcare system (NHS) and society 
perspective. Methods: An individual patient simulation model was adapted to 
estimate the costs and outcomes associated with secondary prophylaxis and on-
demand treatment. The model follows a hypothetical cohort of 1000 patients in a 
lifetime period. The POTTER observational study represented the source for clinical 
data such as clothing factors regimens and consumption, adherence to prophylaxis, 
risk of joint and total bleeds, quality-of-life (QOL) scores and productivity loss. For 
other data such as intracranial haemorrhage and major surgery rate, data from 
published literature were used. Drugs costs were estimated using prices reimbursed 
by the NHS while hospital costs were estimated with national hospital (inpatient 
and outpatient) tariffs. Caregivers’ or patients’ productivity loss was estimated with 
Italian daily Gross Net Product per-capita. Costs and benefits were discounted at 
6.0% in line with published economic evaluations on this subject. Incremental 
cost-effectiveness ratios (ICERs) were calculated. Model outcomes are expressed 
in terms of costs per quality-adjusted-life-years (QALY). Results: As expected, 
mean lifetime costs are higher with secondary prophylaxis than with on-demand 
treatment. Secondary prophylaxis however determines better outcomes in bleed-
ing reduction and better QoL. Using the NHS perspective (considering only direct 
healthcare costs) secondary prophylaxis shows an ICER vs on-demand of € 51,202/
QALY; a more favourable ICER of € 45,432/QALY is shown when considering also indi-
rect costs. ConClusions: Despite the high cost of the pharmacological treatment, 
antihemophilic factor rFVIII-FS in secondary prophylaxis represents a cost-effective 
approach compared with on-demand treatment.
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generated additional 1.5 QALYs with incremental cost-effectiveness ratio of € 1,405 
per QALY. Over lifetime surgery lead to savings of € 5,032, additional 0.8 life years, 
and 4.1 QALYs. In Italy, in the base-case analysis over 10 years bariatric surgery led 
to incremental cost of € 2,552 and generated additional 1.1 QALYs with incremen-
tal cost-effectiveness ratio of € 2,314/QALY. Over lifetime, surgery led to savings of 
€ 8,874, and generated additional 0.5 years of life, and 3.2 QALYs. ConClusions: 
In a comprehensive decision analytic model, a current mix of surgical methods for 
bariatric surgery was cost-effective at 10 years and cost saving over the lifetime 
time horizon in three European countries.
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objeCtives: Controversy surrounds the most appropriate initial treatment regimen 
for Rheumatoid Arthritis. The objective of the present study is to aid in this debate 
by providing cost-effectiveness and cost-utility analyses for four treatment scenar-
ios. Methods: Estimates of costs were applied to outcome data from the Treatment 
of Early Aggressive Rheumatoid Arthritis (TEAR) Trial to determine cost-effective-
ness. Treatment regimens from the TEAR trial, immediate etanercept (IE), immediate 
triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) (IT), step-up 
etanercept (SE), and step-up triple therapy (ST), were compared. Each regimen used 
methotrexate as a background medication. Outcomes analyzed include Disease 
Activity Scores (DAS-28-ESR) from the TEAR trial, calculated Clinical Disease Activity 
Index (CDAI) scores, and Quality-adjusted Life Years (QALYs) calculated using lit-
erature estimates. Discontinuers were assigned cost and outcome estimates based 
on duration of participation and associated outcomes. Analysis was limited to the 
two year time horizon of the TEAR trial. Results: ST was cost-effective for all 
outcome measures, and had the highest net monetary benefit (NMB) for DAS-28-
ESR ($592,569) and QALYs ($71,080), using a willingness to pay (WTP) of $250,000. 
IE was dominated for CDAI and had the lowest NMBs for DAS-28-ESR and QALYs, 
with incremental cost-effectiveness ratios (ICERs) of $1,025,534 and $8,205,670, 
respectively. SE was dominated for all outcomes. Results from one-way and proba-
bilistic sensitivity analysis were consistent with these findings. ConClusions: 
The treatment strategies using etanercept were more costly than triple therapy 
strategies, with similar outcomes and ICERs outside most acceptable levels. SE was 
not cost-effective for any outcome, and ST was a consistently cost-effective treat-
ment strategy.
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objeCtives: Rheumatoid Arthritis (RA) is a chronic, inflammatory disease, affecting 
0.68% of adult population in Greece. RA is associated with decreased quality of life 
and a significant economic burden. The intravenous (IV) formulation of Tocilizumab 
(TCZ) has already proven its efficiency and thus the aim of this study is to evaluate 
and confirm the cost-effectiveness of the subcutaneous (SC) formulation as first line 
biologic monotherapy. Methods: Lifetime costs and outcomes for 10,000 patients 
were projected through an individual simulation model. The analysis compared a 
standard treatment pathway (STP) (Adalimumab, Etanercept and Palliative care) with 
a similar pathway where treatment was initiated with TCZ SC. Health Assessment 
Questionnaire (HAQ) scores were used to reflect disease severity. The primary efficacy 
outcome considered was American College of Rheumatology (ACR) response. Patient 
baseline characteristics derived from the ADACTA trial. Efficacy data were elicited 
from a network meta-analysis. A mapping model transformed HAQ scores into QALYs. 
Clinical practice standards were determined by Expert Opinion (12 Rheumatologists). 
Costs for pharmaceuticals and unit costs for resources were obtained from official 
price lists. Estimated mandatory rebates for new products were taken into account. 
A third-party payer (Social Insurance) perspective was employed. Costs and QALYs 
were discounted at 3%. Results: The treatment sequence starting with TCZ SC 
yielded 0.98 more QALYs (9.08vs. 8.10) at an additional cost of € 27,442.5 (€ 132,733.78 
vs. € 105,291.27) compared to the STP.The Incremental Cost – Effectiveness Ratio (ICER) 
was estimated at € 27,974.28 per QALY gained which is below the national commonly 
used threshold. Probabilistic Sensitivity Analysis confirms robustness of findings 
below a threshold of € 45,000. ConClusions: The results of the analysis suggest that 
TCZ SC can be a cost-effective alternative and provide both patients and health care 
system with more options for RA management due to dual formulation’s effective-
ness and efficiency.
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objeCtives: To evaluate the cost-utility of bariatric surgery in Germany and France 
from a third-party payer perspective over a mid-term (10 years) and a long-term (life-
time) horizon. Methods: A state-transition Markov model was developed, in which 
patients may experience surgery, post-surgery complications, diabetes mellitus type 
2, cardiovascular diseases or die. Transition probabilities, data about effectiveness 
and safety of surgery, costs, and utilities were informed by the literature, patient 
registries and administrative databases. Three types of surgeries were considered: 
gastric bypass, sleeve gastrectomy, and adjustable gastric banding. The model was 
